World Health Organization: 63rd World Health Assembly. Provisional agenda item 11_12; 25 March 2010. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf,
Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA: Living with chronic hepatitis C means ‘you just haven’t got a normal life any more’. Chronic Illn. 2006, 2: 121-131.
CAS
PubMed
Google Scholar
Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB: Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med. 2008, 23: 1959-1965. 10.1007/s11606-008-0790-y.
Article
PubMed
PubMed Central
Google Scholar
Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM: Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci. 2002, 47: 2674-2681. 10.1023/A:1021040702370.
Article
PubMed
Google Scholar
Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, Charlotte F, Piette JC, Moussalli J: Fatigue in patients with chronic hepatitis C. J Viral Hepat. 2002, 9: 295-303. 10.1046/j.1365-2893.2002.00364.x.
Article
CAS
PubMed
Google Scholar
Kallman J, O’Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM: Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci. 2007, 52: 2531-2539. 10.1007/s10620-006-9708-x.
Article
PubMed
Google Scholar
Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH: Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012, 57: 946-952. 10.1016/j.jhep.2012.06.030.
Article
PubMed
PubMed Central
Google Scholar
McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S: Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol. 2002, 17: 171-176. 10.1046/j.1440-1746.2002.02669.x.
Article
PubMed
Google Scholar
Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, Ahl B, Manns MP, Boker KW: Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004, 41: 845-851. 10.1016/j.jhep.2004.07.022.
Article
PubMed
Google Scholar
Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J: Emerging evidence of hepatitis C virus neuroinvasion. AIDS. 2005, 19 (Suppl 3): S140-S144. 10.1097/01.aids.0000192083.41561.00.
Article
PubMed
Google Scholar
Seaman K, Paterson BL, Vallis M, Hirsch G, Peltekian KM: Future directions for investigation of fatigue in chronic hepatitis C viral infection. Chronic Illn. 2009, 5: 115-128. 10.1177/1742395309104476.
Article
PubMed
Google Scholar
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009, 361: 580-593. 10.1056/NEJMoa0808010.
Article
CAS
PubMed
Google Scholar
Casey LC, Lee WM: Hepatitis C therapy update. Curr Opin Gastroenterol. 2012, 28: 188-192. 10.1097/MOG.0b013e3283528e1e.
Article
CAS
PubMed
Google Scholar
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009, 360: 1839-1850. 10.1056/NEJMoa0807650.
Article
CAS
PubMed
Google Scholar
Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J: A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat. 2012, 19 (Suppl 2): 1-26.
Article
PubMed
Google Scholar
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5.
Article
CAS
PubMed
Google Scholar
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.
Article
CAS
PubMed
Google Scholar
Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta E Vale A, Wintfeld N, Green J: The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004, 40: 675-681. 10.1016/j.jhep.2003.12.014.
Article
CAS
PubMed
Google Scholar
Asselah T, Marcellin P: Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012, 32 (Suppl 1): 88-102.
Article
CAS
PubMed
Google Scholar
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364: 1207-1217. 10.1056/NEJMoa1009482.
Article
CAS
PubMed
PubMed Central
Google Scholar
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011, 364: 1195-1206. 10.1056/NEJMoa1010494.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M: Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013, 58: 1918-1929. 10.1002/hep.26641.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hézode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros P, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M: Simeprevir (TMC435) in treatment-experienced HCV genotype 1 patients; the phase IIb, randomized. Controlled ASPIRE trial. Gastroenterology. 2014, 146: 430-441. 10.1053/j.gastro.2013.10.058.
Article
CAS
PubMed
Google Scholar
Kleinman L, Mannix S, Yuan Y, Kummer S, L’Italien G, Revicki D: Review of patient-reported outcome measures in chronic hepatitis C. Health Qual Life Outcomes. 2012, 10: 92-10.1186/1477-7525-10-92.
Article
PubMed
PubMed Central
Google Scholar
Rosa K, Fu M, Gilles L, Cerri K, Peeters M, Bubb J, Scott J: Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes. 2014, 12: 90-10.1186/1477-7525-12-90.
Article
PubMed
PubMed Central
Google Scholar
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989, 46: 1121-1123. 10.1001/archneur.1989.00520460115022.
Article
CAS
PubMed
Google Scholar
Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001, 33: 337-343. 10.3109/07853890109002087.
Article
CAS
PubMed
Google Scholar
Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A: Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010, 25: 805-822. 10.1002/mds.22989.
Article
PubMed
Google Scholar
Gencay-Can A, Can SS: Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int. 2012, 32: 27-31. 10.1007/s00296-010-1558-3.
Article
PubMed
Google Scholar
Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D: Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res. 2000, 9: 499-508. 10.1023/A:1008960710415.
Article
CAS
PubMed
Google Scholar
Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J: Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics. 2003, 21: 341-349. 10.2165/00019053-200321050-00005.
Article
CAS
PubMed
Google Scholar
Blackburn S, Humphrey L, McCool R, Panter C, Young V, Peterson S, Mitchell L, Machouf N, Scott J: Interviews with patients with chronic hepatitis C virus infection document unmet needs, content validity, and comprehension of PROs for Clinical Trials. Poster presented at the 18th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 18-22, 2013, New Orleans, LA, USA
Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002, 35: 704-708. 10.1053/jhep.2002.31311.
Article
PubMed
Google Scholar
Versteegh MM, Rowen D, Brazier JE, Stolk EA: Mapping onto EQ-5D for patients in poor health. Health Qual Life Outcomes. 2010, 8: 141-10.1186/1477-7525-8-141.
Article
PubMed
PubMed Central
Google Scholar
Szende A, Oppe M, Devlin N: EQ-5D Value Sets: Inventory, Comparative Review and User Guide. 2007, Berlin: Springer
Book
Google Scholar
Scott J, Gilles L, Fu M, Peeters M, Brohan E, Amatya R, Jessner W, Beumont-Mauviel M: Adding simeprevir to pegylated interferon-α/ribavirin for HCV shortens time with patient-reported symptoms and impairment in quality of life: results from the simeprevir Phase III QUEST-1, QUEST-2 and PROMISE studies. Poster presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 1-5, 2013, Washington, DC, USA